Last updated on July 2019

A Study of AKR-001 in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)


Brief description of study

This is a multi-center evaluation of AKR-001 in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F3 NASH.

Clinical Study Identifier: NCT03976401

Find a site near you

Start Over

Akero Clinical Study Site

Tucson, AZ United States
  Connect »

Akero Clinical Study Site

Little Rock, AR United States
  Connect »

Akero Clinical Study Site

Huntington Park, CA United States
  Connect »

Akero Clinical Study Site

Los Angeles, CA United States
  Connect »

Akero Clinical Study Site

Boca Raton, FL United States
  Connect »

Akero Clinical Study Site

Lakewood Ranch, FL United States
  Connect »

Akero Clinical Study Site

Port Orange, FL United States
  Connect »

Akero Clinical Study Site

Baton Rouge, LA United States
  Connect »

Akero Clinical Study Site

Marrero, LA United States
  Connect »

Akero Clinical Study Site

Kansas City, MO United States
  Connect »

Akero Clinical Study Site

Berlin, NJ United States
  Connect »

Akero Clinical Study Site

Chattanooga, TN United States
  Connect »

Akero Clinical Study Site

Cedar Park, TX United States
  Connect »

Akero Clinical Study Site

Dallas, TX United States
  Connect »

Akero Clinical Study Site

Edinburg, TX United States
  Connect »

Akero Clinical Study Site

Fort Worth, TX United States
  Connect »

Akero Clinical Study Site

San Antonio, TX United States
  Connect »

Akero Clinical Study Site

Webster, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.